KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA study. PMID 36779691 · Amyloid · 2023-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Economic Evaluation of Three BRAF + MEK Inhibitors for the Treatment of Advanced Unresectable Melanoma With BRAF Mutation From a US Payer Perspective. PMID 36639851 · Ann Pharmacother · 2023-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
CT-Based Radiomic Score: A Risk Stratifier in Far-Advanced Gastric Cancer Patients. PMID 36610930 · Acad Radiol · 2023-Sep The record describes a retrospective radiomics prognostic study, not a Phase III or Phase II/III randomized trial of a drug intervention. The randomization mentioned is for splitting data into training/validation cohorts, not for assigning drug treatments. While it involves oncology, humans, time-to-event endpoints, and a drug context, it fails the core requirement of being an original result report of a randomized drug trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparison of MRI and CT-Based Radiomics and Their Combination for Early Identification of Pathological Response to Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer. PMID 36527425 · J Magn Reson Imaging · 2023-Sep The record describes a retrospective diagnostic/prognostic study evaluating radiomics models for predicting response to neoadjuvant chemotherapy, not a therapeutic randomized controlled trial. While it is randomized, oncology, human, uses a drug, and reports time-to-event endpoints, it does not meet the core requirement of being a Phase III/IIIb or Phase II/III randomized trial of a therapeutic intervention. The phase is not specified, and the study design is diagnostic, not therapeutic.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of radiographer immediate reporting of X-rays of the chest from general practice on the lung cancer pathway (radioX): a randomised controlled trial. PMID 36351688 · Thorax · 2023-Sep Study is a randomized controlled trial in oncology (lung cancer) but evaluates a diagnostic/imaging process (immediate radiographer reporting) not a drug intervention, and the primary endpoint is time-to-diagnosis, which is not a standard time-to-event efficacy endpoint like OS, PFS, or DFS. No Phase III/IIIb or Phase II/III designation is explicitly stated.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Reduced prescription of TNF-inhibitors in chronic arthritis based on therapeutic drug monitoring: A randomized controlled trial. PMID 36315419 · Scand J Rheumatol · 2023-Sep The study is a randomized controlled trial with drug intervention (TNF-inhibitors) and primary results, but it is not an oncology study and lacks a time-to-event efficacy endpoint.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancer. PMID 37991939 · JNCI Cancer Spectr · 2023-Oct-31 The record describes a secondary analysis (prognostic/predictive effect of BMI) from a randomized trial, not the original primary result report of the trial comparing 6 vs 3 years of anastrozole. The trial phase is not explicitly stated in the provided metadata as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy, safety and pharmacokinetics of apatinib plus etoposide versus apatinib alone for platinum-resistant recurrent ovarian cancer: protocol of a multicenter, open-label, randomized phase 2 trial. PMID 37969395 · Transl Cancer Res · 2023-Oct-31 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Degradable Starch Microspheres Transarterial Chemoembolization with or without Lipiodol for Liver Metastases from Pancreatic Cancer: A Prospective Randomized Trial. PMID 37958413 · Cancers (Basel) · 2023-Oct-31 The record is a prospective randomized oncology trial with a drug intervention and primary time-to-event endpoint (OS), but the abstract does not explicitly state the trial phase (e.g., Phase II, III), and the provided deterministic review indicates phase evidence is unclear. Therefore, it cannot be confirmed as a Phase III/IIIb or Phase II/III trial, which is a required eligibility criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prognostic factors and survival prediction of resected non-small cell lung cancer with ipsilateral pulmonary metastases: a study based on the Surveillance, Epidemiology, and End Results (SEER) database. PMID 37899470 · BMC Pulm Med · 2023-Oct-30 This is a retrospective prognostic modeling study using the SEER database, not a randomized controlled trial. While it has oncology focus, human subjects, and a time-to-event endpoint (OS), it lacks the required elements of a drug-intervention RCT in Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Construction of web-based prediction nomogram models for cancer-specific survival in patients at stage IV of hepatocellular carcinoma depending on SEER database. PMID 38432884 · Zhong Nan Da Xue Xue Bao Yi Xue Ban · 2023-Oct-28 The record describes a prognostic nomogram construction study using a retrospective database (SEER), not a report of a randomized Phase III clinical trial. While it involves oncology, humans, and mentions chemotherapy as a prognostic factor, it does not meet the core criteria of being a formal result report from a Phase III/IIIb or Phase II/III randomized drug trial with a primary/key secondary time-to-event efficacy endpoint (OS, PFS, etc.) for comparing drug interventions. The 'Randomized Controlled Trial' publication type is likely a misclassification, as the study involves random splitting of a retrospective cohort into training/validation sets, not randomization of patients to different drug interventions.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Namodenoson Inhibits the Growth of Pancreatic Carcinoma via Deregulation of the Wnt/β-catenin, NF-κB, and RAS Signaling Pathways. PMID 38002266 · Biomolecules · 2023-Oct-27 仅见动物/临床前证据,不是人体临床试验。
B
仅广召回影子组 excludednon_human pending 0 Figure · 0 Panel · risk -
A blinded-endpoint, randomized controlled trial of Sanyrene with natural active ingredient for prophylaxis of radiation dermatitis in patients receiving radiotherapy. PMID 37891689 · Radiat Oncol · 2023-Oct-27 While the study is a randomized, controlled, oncology trial with a drug intervention and a time-to-event endpoint, it does not meet the requirement for a primary/key secondary oncology efficacy endpoint (e.g., OS, PFS, DFS). The primary endpoint is the prevention of radiation dermatitis, a toxicity outcome, not a tumor-related efficacy endpoint. Furthermore, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparison of the safety and persistence of immunogenicity of bivalent HPV16/18 vaccine in healthy 9-14-year-old and 18-26-year-old Chinese females: A randomized, double-blind, non-inferiority clinical trial. PMID 39492306 · Vaccine · 2023-Oct-26 The study is a randomized Phase 3b trial of a drug (HPV vaccine) in humans, but it is not an oncology trial (it is a vaccine prevention study). Furthermore, its primary endpoints are immunogenicity (antibody titers) and safety, not a time-to-event efficacy endpoint (OS, PFS, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Application of statistical machine learning in biomarker selection. PMID 37884606 · Sci Rep · 2023-Oct-26 The record describes a secondary biomarker analysis using machine learning methods on data from the JAVELIN Bladder 100 trial. It is not the original report of the trial's efficacy results.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Narrative review-diagnosing and managing malignant epidural spinal cord compression: an evidence-based approach. PMID 37970608 · Ann Transl Med · 2023-Oct-25 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Statin use and the risk of hepatocellular carcinoma among patients with chronic hepatitis B: an emulated target trial using longitudinal nationwide population cohort data. PMID 37880589 · BMC Gastroenterol · 2023-Oct-25 The study is an observational cohort analysis emulating a target trial, not a randomized Phase III/IIIb or Phase II/III clinical trial with a drug-containing intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
[Analysis of short-term efficacy of perioperative fecal microbiota transplantation combined with nutritional support in patients with radiation-induced enteritis complicated by intestinal obstruction]. PMID 37849266 · Zhonghua Wei Chang Wai Ke Za Zhi · 2023-Oct-25 The study is a randomized trial in oncology patients but evaluates a non-drug intervention (fecal microbiota transplantation) and reports only short-term recovery, complication, quality-of-life, and nutritional outcomes. It lacks a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) and the clinical trial phase is unspecified.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A novel rapamycin cream formulation improves facial angiofibromas associated with tuberous sclerosis complex: a double-blind randomized placebo-controlled trial. PMID 37463422 · Br J Dermatol · 2023-Oct-25 未发现恶性肿瘤人群证据。
B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of therapeutic HPV vaccines to treat CIN 2/CIN 3 lesions: a systematic review and meta-analysis of phase II/III clinical trials. PMID 37879679 · BMJ Open · 2023-Oct-24 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial. PMID 37875494 · Nat Commun · 2023-Oct-24 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
More intensive therapy as more effective treatment for frail patients with multiple myeloma [corrected]. PMID 37582048 · Blood Adv · 2023-Oct-24 The record describes a randomized analysis comparing VRd vs Rd for multiple myeloma, reporting overall survival hazard ratios, and is classified as a randomized controlled trial in publication types. However, the explicit phase (e.g., Phase III) is not confirmed in the provided metadata (title, abstract, or publication types), so the phase criterion cannot be definitively established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Influence of the Anesthetic Technique on Circulating Extracellular Vesicles in Bladder Cancer Patients Undergoing Radical Cystectomy: A Prospective, Randomized Trial. PMID 37887347 · Cells · 2023-Oct-23 While oncology, human, randomized, and original with a drug intervention, the study does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or HR. The primary outcome is extracellular vesicle concentration and micro-RNA expression, which is a biomarker/mechanistic endpoint, not an efficacy endpoint as required.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Synbiotics, prebiotics and probiotics for people with chronic kidney disease. PMID 37870148 · Cochrane Database Syst Rev · 2023-Oct-23 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Determining the Effectiveness of Fibrin Sealants in Reducing Complications in Patients Undergoing Lateral Neck Dissection (DEFeND): A Randomised External Pilot Trial. PMID 37894440 · Cancers (Basel) · 2023-Oct-20 The study is an original randomized pilot trial in oncology, but it fails multiple core eligibility criteria: it is not a definitive Phase III trial, it lacks a drug intervention (fibrin sealant is not considered a drug per the criteria), and it does not report a time-to-event efficacy endpoint (OS, PFS, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Preservation versus resection of Denonvilliers' fascia in total mesorectal excision for male rectal cancer: follow-up analysis of the randomized PUF-01 trial. PMID 37863878 · Nat Commun · 2023-Oct-20 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Long-Term Outcomes in Patients With Localized Ewing Sarcoma Treated With Interval-Compressed Chemotherapy on Children's Oncology Group Study AEWS0031. PMID 37651654 · J Clin Oncol · 2023-Oct-20 This is an updated report of long-term outcomes from the Phase III randomized trial COG AEWS0031, which was a definitive oncology trial comparing interval-compressed vs standard timing chemotherapy. The abstract explicitly reports EFS and OS results with p-values, confirming it's a formal result report with primary time-to-event efficacy endpoints. The trial is clearly Phase III based on its design and scope (Children's Oncology Group study with 568 patients), though the abstract doesn't explicitly state 'Phase III'. The randomized, drug-intervention, and oncology criteria are all clearly met.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
The Effect of a Six-Week Nordic Walking Training Cycle on Oxidative Damage of Macromolecules and Iron Metabolism in Older Patients with Multiple Myeloma in Remission-Randomized Clinical Trial. PMID 37895038 · Int J Mol Sci · 2023-Oct-19 Study is a randomized trial in oncology but evaluates a non-drug intervention (Nordic walking) and measures biomarker changes (iron metabolism, oxidative stress), not a time-to-event efficacy endpoint like OS or PFS. No drug intervention is present, and Phase III is not established.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Development and validation of a nomogram to predict cancer-specific survival in nonsurgically treated elderly patients with prostate cancer. PMID 37853026 · Sci Rep · 2023-Oct-18 The record is not eligible because it is a retrospective prognostic model development study using a population database (SEER), not a randomized clinical trial evaluating a drug intervention. While it is oncology, involves humans, includes a randomized split for model validation, and has a time-to-event endpoint (CSS), it lacks a drug intervention and is not a Phase III/IIIb trial reporting efficacy results from an experimental therapy.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Testing a Model of Care for Patients on Immune Checkpoint Inhibitors Based on Electronic Patient-Reported Outcomes: Protocol for a Randomized Phase II Controlled Trial. PMID 37851498 · JMIR Res Protoc · 2023-Oct-18 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
SPOTlight on GLOW. PMID 37852180 · Cell Rep Med · 2023-Oct-17 The record describes the primary results of a Phase III randomized oncology trial with a drug intervention. While the abstract snippet does not explicitly name an endpoint like OS or PFS, the context of a Phase III oncology trial with 'improves outcome' strongly implies a standard time-to-event primary efficacy endpoint. The deterministic review's 'no_time_to_event_signal' flag is based on missing explicit signal, but the overall context is sufficient for eligibility.
H L B
旧查询独有 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial. PMID 37391938 · Int J Cancer · 2023-Oct-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Reduced Relapse-Free Survival in Colorectal Cancer Patients with Elevated Soluble CD40 Ligand Levels Improved by Vitamin D Supplementation. PMID 37892436 · Nutrients · 2023-Oct-13 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial. PMID 37594724 · Clin Cancer Res · 2023-Oct-13 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial. PMID 37566240 · Clin Cancer Res · 2023-Oct-13 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Stereotactic Body Radiotherapy Combined with Camrelizumab and Apatinib in Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. PMID 37556120 · Clin Cancer Res · 2023-Oct-13 The trial is a randomized study in oncology with a drug intervention and time-to-event endpoints, but the phase is not explicitly stated in the provided record. The metadata indicates uncertainty ('phase3_evidence_unclear'). Without explicit confirmation that it is a Phase III/IIIb or Phase II/III trial, it cannot be included per the strict criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Tumor Microenvironment Modifications Induced by Afatinib in Squamous Cell Carcinoma of the Head and Neck: A Window-of-Opportunity Study (EORTC-90111-24111). PMID 37531234 · Clin Cancer Res · 2023-Oct-13 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Minimally invasive versus open pancreatoduodenectomy for pancreatic and peri-ampullary neoplasm (DIPLOMA-2): study protocol for an international multicenter patient-blinded randomized controlled trial. PMID 37828593 · Trials · 2023-Oct-12 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Association of Radiochemotherapy to Immunotherapy in unresectable locally advanced Oesophageal carciNoma-randomized phase 2 trial ARION UCGI 33/PRODIGE 67: the study protocol. PMID 37828434 · BMC Cancer · 2023-Oct-12 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Patient-led home-based follow-up after surgery for colorectal cancer: the protocol of the prospective, multicentre FUTURE-primary implementation study. PMID 37827744 · BMJ Open · 2023-Oct-12 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Selection of Chemotherapy in Advanced Poorly Differentiated Extra-Pulmonary Neuroendocrine Carcinoma. PMID 37894318 · Cancers (Basel) · 2023-Oct-11 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
N1 lymph node detection in lymph node harvesting in non-small cell lung cancer: Formaldehyde exposure is a drawback? PMID 37817262 · J Cardiothorac Surg · 2023-Oct-10 Record describes a randomized comparison of two lymph node dissection methods (surgical vs. pathology) for staging in non-small cell lung cancer. It is an oncology, human, randomized, original result report. However, it does not meet key eligibility criteria: 1) No drug-containing intervention is present (intervention is surgical/pathological technique), 2) No explicit Phase III/IIIb or Phase II/III trial phase is stated in metadata, and 3) The primary endpoints are staging/detection rates and lymph node counts, not a time-to-event efficacy endpoint (e.g., OS, PFS). Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Multimodal prehabilitation to improve the clinical outcomes of frail elderly patients with gastric cancer: a study protocol for a multicentre randomised controlled trial (GISSG+2201). PMID 37816552 · BMJ Open · 2023-Oct-10 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial. PMID 37450382 · Blood Adv · 2023-Oct-10 The trial is randomized, oncology-related, and reports original results. However, it fails the primary criterion of having a time-to-event efficacy endpoint (e.g., OS, PFS, DFS) as the primary or key secondary outcome; the primary endpoint is infection incidence (a binary outcome), not a survival or progression-free time-to-event analysis. The phase is not specified as Phase III/IIIb or II/III. Therefore, it is not eligible for the KM digitization cohort.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Hematological Toxicities with PARP Inhibitors in Prostate Cancer: A Systematic Review and Meta-Analysis of Phase II/III Randomized Controlled Trials. PMID 37835597 · Cancers (Basel) · 2023-Oct-09 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The iBLAD study: patient-reported outcomes in bladder cancer during oncological treatment: a multicenter national randomized controlled trial. PMID 37812306 · J Patient Rep Outcomes · 2023-Oct-09 The study is a randomized controlled trial in human oncology with a drug intervention context and a reported OS endpoint. However, it does not meet two critical eligibility criteria: 1) The trial phase is not explicitly confirmed as Phase III/IIIb or Phase II/III in the provided metadata, and 2) The primary experimental intervention is a patient-reported outcome monitoring system, not a drug-containing regimen. The drug therapy (chemo/immunotherapy) is part of standard care in both arms.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: The randomized GUIDANCE-01 trial. PMID 37774697 · Cancer Cell · 2023-Oct-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Genetically informed therapy for lymphoma: the discomfiting benefit of lumping splits. PMID 37774696 · Cancer Cell · 2023-Oct-09 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas. PMID 37835565 · Cancers (Basel) · 2023-Oct-06 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Antidepressants for the prevention of depression following first-episode psychosis (ADEPP): study protocol for a multi-centre, double-blind, randomised controlled trial. PMID 37803384 · Trials · 2023-Oct-06 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -